BR112012006389A2 - agente de depiração peptídica, métodos para produzir um agente de depuração peptídica, e de terapia de pró-droga de enzima direcionada ao anticorpo, e, uso de um peptídeo - Google Patents

agente de depiração peptídica, métodos para produzir um agente de depuração peptídica, e de terapia de pró-droga de enzima direcionada ao anticorpo, e, uso de um peptídeo

Info

Publication number
BR112012006389A2
BR112012006389A2 BR112012006389A BR112012006389A BR112012006389A2 BR 112012006389 A2 BR112012006389 A2 BR 112012006389A2 BR 112012006389 A BR112012006389 A BR 112012006389A BR 112012006389 A BR112012006389 A BR 112012006389A BR 112012006389 A2 BR112012006389 A2 BR 112012006389A2
Authority
BR
Brazil
Prior art keywords
peptide
enzyme
clearance
agent
producing
Prior art date
Application number
BR112012006389A
Other languages
English (en)
Inventor
James Alexander Schouten
Paul James Davis
Original Assignee
Mologic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mologic Ltd filed Critical Mologic Ltd
Publication of BR112012006389A2 publication Critical patent/BR112012006389A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

agente de depuração peptídica, métodos para produzir um agente de depuração peptídica, e de terapia de pró-droga de enzima direcionada ao anticorpo, e, uso de um peptídeo. um agente de depuração de peptídeo é fornecido para a depuração de um conjugado de uma enzima e uma molécula de ligação que liga especificamente ao local alvo a partir de um local não alvo em um paciente. o agente de depuração de peptídeo liga ao local ativo da enzima. o peptídeo também liga ao receptor de asialoglicoproteína expressado pelas células hepáticas para facilitar a depuração através do fígado. o peptídeo pode ser glicosilado para facilitar a depuração através do figado pela ligação às células hepáticas que expressam um receptor de asialoglicoproteína. tipicamente, o peptídeo previne ou inibe a atividade enzimática na ligação à enzima e não é substancialmente modificado pela atividade enzimática. o peptídeo pode ter base em ácido dipeptídeo amino-naftóico (ana) - glutamato (glu) e pode compreender a sequência de amino ácido serina (ser) - alanina (ala) - ácido amino-naftóico (ana) - glutamato (glu). em tais casos, a enzima de interesse é tipicamente cpg2.
BR112012006389A 2009-09-23 2010-09-23 agente de depiração peptídica, métodos para produzir um agente de depuração peptídica, e de terapia de pró-droga de enzima direcionada ao anticorpo, e, uso de um peptídeo BR112012006389A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0916749.5A GB0916749D0 (en) 2009-09-23 2009-09-23 Peptide cleaning agents
PCT/GB2010/001796 WO2011036457A1 (en) 2009-09-23 2010-09-23 Peptide clearing agents

Publications (1)

Publication Number Publication Date
BR112012006389A2 true BR112012006389A2 (pt) 2016-11-22

Family

ID=41327500

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012006389A BR112012006389A2 (pt) 2009-09-23 2010-09-23 agente de depiração peptídica, métodos para produzir um agente de depuração peptídica, e de terapia de pró-droga de enzima direcionada ao anticorpo, e, uso de um peptídeo

Country Status (16)

Country Link
US (1) US8846861B2 (pt)
EP (1) EP2470216A1 (pt)
JP (1) JP2013505287A (pt)
KR (1) KR20120084298A (pt)
CN (1) CN102665768B (pt)
AU (1) AU2010299643B2 (pt)
BR (1) BR112012006389A2 (pt)
CA (1) CA2774081A1 (pt)
GB (1) GB0916749D0 (pt)
IL (1) IL218713A0 (pt)
IN (1) IN2012DN02241A (pt)
MX (1) MX2012003565A (pt)
NZ (1) NZ598802A (pt)
SG (1) SG179015A1 (pt)
WO (1) WO2011036457A1 (pt)
ZA (1) ZA201201527B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2435510A (en) 2006-02-23 2007-08-29 Mologic Ltd Enzyme detection product and methods
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
JP6017422B2 (ja) 2010-08-10 2016-11-02 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 赤血球結合療法
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
ES2874884T3 (es) 2014-02-21 2021-11-05 Ecole Polytechnique Fed De Lausanne Epfl Epfl Tto Compuestos terapéuticos dirigidos a la glucosa
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
MX2022009419A (es) 2020-01-31 2022-08-25 Avilar Therapeutics Inc Compuestos de union al asgpr para la degradacion de proteinas extracelulares.
JP2024517812A (ja) 2021-05-03 2024-04-23 アヴィラー セラピューティクス インコーポレイテッド 免疫グロブリン及びその他のタンパク質を分解する強力なａｓｇｐｒ結合性化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075010A (en) 1992-06-09 2000-06-13 Neorx Corporation Small molecular weight ligand-hexose containing clearing agents
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
US20030068322A1 (en) 1988-04-18 2003-04-10 Immunomedics, Inc. Methods of antibody-directed enzyme-prodrug therapy
CA2082507A1 (en) 1990-05-11 1991-11-12 George Y. Wu Targeted protection from cytotoxins
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
DE69638134D1 (de) 1995-06-07 2010-04-08 Immunomedics Inc Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort
GB9524942D0 (en) 1995-12-06 1996-02-07 Aepact Ltd Drug therapy
EP0937253A1 (en) * 1996-10-31 1999-08-25 Novalon Pharmaceutical Corporation Identification of drugs using complementary combinatorial libraries
GB9624993D0 (en) * 1996-11-30 1997-01-15 Aepact Ltd Tumour therapy
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
WO2000017226A1 (en) * 1998-09-23 2000-03-30 The Regents Of The University Of California Synthetic peptides, conjugation reagents and methods
JP2004535560A (ja) * 2001-04-20 2004-11-25 ザ ユニヴァーシティ オブ ジョージア リサーチファウンデーション， インク． 活性部位不活性化因子
JP2009509535A (ja) * 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
EP2050761B1 (en) 2007-10-16 2011-06-29 Toscana Biomarkers S.r.l. Galactosylated peptides, their preparation and use in autoimmune diseases diagnosis

Also Published As

Publication number Publication date
ZA201201527B (en) 2013-05-29
US20130053543A1 (en) 2013-02-28
US8846861B2 (en) 2014-09-30
IN2012DN02241A (pt) 2015-08-21
JP2013505287A (ja) 2013-02-14
EP2470216A1 (en) 2012-07-04
SG179015A1 (en) 2012-04-27
GB0916749D0 (en) 2009-11-04
AU2010299643A1 (en) 2012-03-22
AU2010299643B2 (en) 2014-06-26
CN102665768A (zh) 2012-09-12
KR20120084298A (ko) 2012-07-27
WO2011036457A1 (en) 2011-03-31
CA2774081A1 (en) 2011-03-31
IL218713A0 (en) 2012-05-31
CN102665768B (zh) 2015-01-21
NZ598802A (en) 2013-10-25
MX2012003565A (es) 2012-08-03

Similar Documents

Publication Publication Date Title
BR112012006389A2 (pt) agente de depiração peptídica, métodos para produzir um agente de depuração peptídica, e de terapia de pró-droga de enzima direcionada ao anticorpo, e, uso de um peptídeo
BRPI1015424A2 (pt) métodos e composições utilizando peptídeos e proteínas com elementos de terminação c.
BRPI0508670A (pt) proteìnas de buganina modificada, citotoxinas e métodos e usos delas
BR112014006390A2 (pt) anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
WO2007135196A3 (en) Stable soluble salts of phenylbenzimidazole sulfonic acid at phs at or below 7.0
BR112012029689A2 (pt) proteína de fusão sequência de polinucleotídeo, célula hospedeira, composição farmacêutica e uso.
BR112013017080A8 (pt) Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente
BRPI0914319B8 (pt) imunoligante que se liga especificamente ao tnf alfa humano e composição
BRPI0922350B8 (pt) anticorpo humano que se liga ao fator de tecido humano e molécula biespecífica e seus usos, célula hospedeira eucariótica ou procariótica recombinante, composição farmacêutica, método para a produção de um anticorpo, composição de diagnóstico, método para detectar a presença de fator de tecido em uma amostra in vitro, kit para detectar a presença de fator de tecido em uma amostra eanticorpo antiidiotípico
UY31533A1 (es) Moleculas de enlace al receptor humano ox40
BR112012009854B8 (pt) proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, método de confecção da referida proteína de ligação e uso da mesma
BR112012018947B1 (pt) anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica
BR112012018951C8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
NI201200134A (es) Polipéptidos agonistas que se enlazan a dr5
BR112012009227A2 (pt) métodos e sistemas para purificar neurotoxina botulínica não complexada
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
EA201201446A1 (ru) Пептидные производные, их получение и применение
AR066199A1 (es) Metodo para reducir la concentracion del peptido amiloide beta
BRPI0919020A2 (pt) Uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
BRPI0720500A8 (pt) Preparação líquida transdérmica
BR112012010661A2 (pt) método para tratar insuficiência cardíaca com peptídeos semelhantes à estressecopina
Wang et al. Discovery of natural product ellagic acid as a potent CD73 and CD39 dual inhibitor
BR112014027213A8 (pt) nova composição de alfentanil para o tratamento de dor aguda
BR112012030084A2 (pt) peptídeos que se ligam a receptores do fator de crescimento semelhante à insulina tipo 1

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/54 (2017.01), A61K 47/66 (2017.01), B82Y 5